* Epix Medical Inc., of Cambridge, Mass., and Mallinckrodt Inc., of St. Louis, expanded resources for research and development of their magnetic resonance imaging (MRI) technologies. Mallinckrodt has exercised its option to co-fund advanced research for intravascular MRI agents, and has provided for expansion of the clinical strategy for AngioMARK (MS-325), an imaging agent that recently completed a Phase II clinical trial for a peripheral vascular indication. No specific terms were disclosed in the widening of the collaboration.
* The Liposome Company Inc., of Princeton, N.J., received approval from the Therapeutic Goods Administration in Australia to market Abelcet (Amphotericin B Lipid Complex Injection) for the first-line treatment of invasive fungal disease caused by organisms susceptible to amphotericin B, such as Candida, Aspergillus and Cryptococcus. Abelcet is marketed in the U.S. for treatment of severe, systemic fungal infections in patients refractory to or intolerant of conventional therapy.
* Scios Inc., of Mountain View, Calif., and SmithKline Beecham plc, of London, said Scios will copromote Paxil (paroxetine HC1) in the U.S. Last year, the drug was the fastest growing major product in the selective serotonin re-uptake inhibitor antidepressant market and in the anti-anxiety market. The drug, which regulates serotonin, is approved to treat depression, panic disorder and obsessive-compulsive disorder.
* Vysis Inc., of Downers Grove, Ill., filed an application in France with the Agence du Medicament for registration of its PathVysion HER-2 DNA Probe Kit, a diagnostic test to detect and quantify the HER-2 gene in breast cancer patients. Registration will allow Vysis to market the product throughout Europe.